1128-53-6

Basic information

• Product Name: 1-Phenyl-1H-pyrazol-4-amine
• Synonyms: 1-Phenyl-1H-pyrazol-4-amine
• CAS NO: 1128-53-6
• Molecular Formula: C₉H₉N₃
• Molecular Weight: 159.19
• Mol File: 1128-53-6.mol

Chemical Properties

• Melting Point: 104-105 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 305.4°C at 760 mmHg
• Flash Point: 138.5°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 0.000822mmHg at 25°C
• Refractive Index: 1.641
• PKA: 4.45±0.10(Predicted)
• CAS DataBase Reference: 1-Phenyl-1H-pyrazol-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Phenyl-1H-pyrazol-4-amine(1128-53-6)
• EPA Substance Registry System: 1-Phenyl-1H-pyrazol-4-amine(1128-53-6)

Safety Data

• Hazardous Substances Data: 1128-53-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Phenyl-1H-pyrazol-4-amine is used as an analgesic for its ability to relieve mild to moderate pain, such as headaches, dental pain, and muscle aches. It is valued for its effectiveness in reducing discomfort and is commonly found in over-the-counter medications.
1-Phenyl-1H-pyrazol-4-amine is also used as an antipyretic to reduce fever by lowering the body's temperature. Its capacity to mitigate the heat generated by the immune response makes it a useful component in fever management.
Additionally, due to its role in inhibiting prostaglandin production, 1-Phenyl-1H-pyrazol-4-amine is used in the development of combination drugs, where it can enhance the therapeutic effects of other medications, particularly in the treatment of pain and fever.
While generally considered safe when used as directed, it is important to be aware of potential side effects and interactions with other drugs, which underscores the need for responsible use and medical supervision.

InChI:InChI=1/C9H9N3/c10-8-6-11-12(7-8)9-4-2-1-3-5-9/h1-7H,10H2

Upstream product

• 108-86-1 bromobenzene 
• 28466-26-4 4-aminopyrazole 
• 591-50-4 iodobenzene 
• 15115-52-3 4-bromo-1-phenyl-1H-pyrazole 
• 98-80-6 phenylboronic acid 
• 19218-70-3 mesoxalaldehyde tris-phenylhydrazone 
• 3994-48-7 4-nitro-1-phenylyrazole 
• 25503-12-2 1-phenyl-4-phenylazo-1H-pyrazole 

Downstream Products

• 77763-10-1 amino-6 phenyl-1 pyrazolo <4,3-b> pyridine 
• 343223-86-9 carboxy-6 phenyl-1 pyrazolo <4,3-b> pyridine 
• 343223-85-8 carbamoyl-6 phenyl-1 pyrazolo <4,3-b> pyridine 
• 343230-84-2 carbethoxy-6 phenyl-1 pyrazolo <4,3-b> pyridine 
• 343232-82-6 carbethoxy-6 chloro-7 phenyl-1 pyrazolo <4,3-b> pyridine 
• 77763-06-5 9-Oxo-1-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f][1,7]naphthyridine-8-carboxylic acid 
• 77763-05-4 9-Oxo-1-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f][1,7]naphthyridine-8-carboxylic acid ethyl ester 
• 77763-07-6 6-Ethyl-9-oxo-1-phenyl-6,9-dihydro-1H-pyrazolo[3,4-f][1,7]naphthyridine-8-carboxylic acid 
• 77763-16-7 (phenyl-1 pyrazolo <4,3-b> pyridyl)-6 aminomethylene malonate d'ethyle 
• 328232-91-3 trans-3-oxo-N-(1-phenyl-1H-pyrazol-4-yl)-3H-spiro[4-aza-2-benzofuran-1,1'-cyclohexane]-4'-carboxamide 
• 1637587-34-8 1-phenyl-4-(pyrimidin-2-ylamino)-1H-pyrazole-5-carbonitrile 
• 1637587-43-9 1-phenyl-4-(quinazolin-2-ylamino)-1H-pyrazole-5-carbonitrile 
• 1637587-11-1 N-(1-phenyl-1H-pyrazol-4-yl)pyrimidin-2-amine 
• 1637587-20-2 N-(1-phenyl-1H-pyrazol-4-yl)quinazolin-2-amine 

Relevant articles and documents

Identification and Biological Evaluation of Novel Type II B-RafV600E Inhibitors

The mitogen-activated protein kinase (MAPK) pathway plays a vital role in signal transduction networks. Severe diseases may be triggered if it is disturbed by mutated components, especially the kinase B-RafV600E. New inhibitors of the kinase ar

Copper-Catalyzed N1 Coupling of 3-Aminoindazoles and Related Aminoazoles with Aryl Bromides

The N1-selective arylation of 3-aminoindazoles using copper catalysis is herein reported. The reaction uses readily accessible aryl bromides as coupling partners, including those from heterocycles, and allows easy access to a broad variety of substituted 3-aminoindazoles. The methodology was also examined on other aminoazoles of interest for the pharmaceutical industry.

Design and synthesis of anti-tumor compounds containing ferulic acid-pyrazole skeleton

The invention discloses design and a preparation method of an anti-tumor compound containing a ferulic acid-pyrazole skeleton. The structure of the anti-tumor compound is shown as a formula in the specification.

HSP90 INHIBITORS AND USES THEREOF

Herein is described the design and synthesis of resorcylate aminopyrazole compounds. These compounds show broad, potent and fungal-selective Hsp90 inhibitory activity. These compounds also find use in treating Hsp90 related deseases.

Cu-Catalyzed Couplings of Heteroaryl Primary Amines and (Hetero)aryl Bromides with 6-Hydroxypicolinamide Ligands

A family of 6-hydroxypicolinamide ligands have been identified as effective supporting ligands for Cu-catalyzed couplings of heteroaryl bromides and chlorides with heteroaryl primary amines. The C-N couplings are carried out at 80-120 °C in DMSO or sulfolane using K2CO3 or K3PO4 as the base with 2-10 mol % CuI and supporting ligand. The strength of the base was found to have an impact on the chemoselectivity and rate. The use of K2CO3 as the base enabled selective C-N coupling of aryl bromides over aryl chlorides with 2-5 mol % Cu at 80-120 °C. With K3PO4 as the base, aryl chlorides are capable of undergoing C-N coupling, though 5-10 mol % Cu is required at 120-130 °C. Members of the ligand family are straightforward to prepare in one step from 6-hydroxypicolinic acid and the corresponding anilines.

IRAK4 INHIBITOR AND USE THEREOF

The present invention relates to a compound inhibiting the activity of an IRAK4 kinase, a pharmaceutical composition thereof, a use thereof in preparing drugs, a method in which same is used for inhibiting the activity of the IRAK4 kinase and a method in which same is used for treating and/or preventing IRAK4 kinase mediated diseases or conditions in mammals (particularly humans). The compound has a structural formula I.

Design of potent B-RafV600E inhibitors by multiple copy simulation search strategy

B-Raf kinase is a vital intermedium in the mitogen-activated protein kinase (MAPK) signaling pathway, which transforms extracellular signals into cellular mechanisms. Mutations in this kinase, for instance, the most common V600E mutation, can lead to the ERK signaling pathologically activated and hence cause severe diseases such as somatic tumors. So far, the development of B-Raf inhibitors has made remarkable progress. However, the resistance and relapse of approved Raf drugs have been widely reported, and the optimization for old drugs and the discovery for new inhibitors still remain a significant task. In this study, we designed and evaluated a series of novel B-RafV600E inhibitors. A fragment library has been established before the docking simulation carried out using the MCSS strategy (multicopy simulation search). The appropriate fragments were reassembled to provide new candidate compounds, which were further screened by iterative docking simulations and molecular dynamics. Bioassays were carried out to evaluate the pharmacological profile of the compounds identified and synthesized. The result showed that compound 5n had an impressive enzyme inhibitory and antiproliferation activity, suggesting a promising potential in the future study.

Design, synthesis, and biological evaluation of pyrazole derivatives containing acetamide bond as potential BRAFV600E inhibitors

With the increasingly acquired resistance, relapse and side effects of known marketed BRAFV600E inhibitors, it's significant to design the more effective and novel drugs. In this study, a series of novel pyrazole derivatives containing acetamid

Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity

Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has been hampered by a lack of selective inhibitors. This work introduces a class of depsipeptidic KLK6 inhibitors, discovered via high-throughput screening, which were found to function as substrate mimics that transiently acylate the catalytic serine of KLK6. Detailed structure-activity relationship studies, aided by in silico modeling, uncovered strict structural requirements for potency, stability, and acyl-enzyme complex half-life. An optimized scaffold, DKFZ-251, demonstrated good selectivity for KLK6 compared to other KLKs, and on-target activity in a cellular assay. Moreover, DKFZ-633, an inhibitor-derived activity-based probe, could be used to pull down active endogenous KLK6.

Design and synthesis of diphenyl urea derivative anti-tumor compounds containing pyrazol frameworks

The invention discloses diphenyl urea derivatives containing pyrazol frameworks and a prepration method thereof. The structural formula of the diphenyl urea derivatives containing pyrazol frameworks is as shown in the specification, wherein R1 is selected